Patient Screening in IV Therapy

By Cheryl Lomax, Director of Clinical Life Sciences

Because screening is the safety gate for everything that follows. IV therapy delivers fluids and nutrients straight into the bloodstream, bypassing the body’s natural digestive safeguards, so it works fast and leaves little room to undo a wrong decision. Screening confirms, before anything is administered, that a treatment is safe, appropriate and genuinely beneficial for that specific individual. It is where both personalization and patient safety begin.

IV therapy is a clinical intervention, not an off-the-shelf product. Certain conditions, for example kidney or heart disease, uncontrolled blood pressure, specific allergies, or G6PD deficiency with high-dose vitamin C can make infusions unsafe, and some ingredients interact with existing medications. Qualification simply confirms that, for this person, the benefit clearly outweighs the risk.

A full medical and surgical history, current medications and supplements, allergies, relevant conditions (cardiac, renal, hepatic, diabetes etc), any previous reactions to IVs or injection, and the person’s goals or symptoms. Baseline observations (such as blood pressure) and blood or biomarker results. This should be captured on a signed medical screening and disclaimer, with a prescription from a qualified prescriber for any prescriptive treatment.

An infusion can help one person and harm another. Health status determines the safe fluid volume, the appropriate ingredients and doses, and whether monitoring is needed during treatment. Someone with hypertension or cardiac or renal issues, for instance, may not tolerate certain volumes or electrolytes. Understanding status lets the provider anticipate and prevent problems rather than react to them.

Yes, and that is exactly the point of doing it. A screening might adjust the formulation, dose or fluid volume, defer treatment pending GP or specialist clearance, decline it altogether, or point the person toward a more suitable option. A good provider treats screening as a genuine decision point, not a box-ticking formality.

Missed contraindications and drug interactions, allergic or anaphylactic reactions, fluid overload, electrolyte disturbances, and the masking of an underlying condition that needed attention, as well as administering an inappropriate or unapproved formulation. Beyond the direct risk to the patient, it exposes the clinic to clinical-incident, regulatory and medico-legal consequences.

Clinical governance is what makes safety consistent rather than dependent on whoever happens to be on shift. It covers standardized protocols, approved formularies, prescriptions signed by a registered prescriber, incident reporting, correct medicine storage and segregation, and regular audit. Together these ensure every patient receives the same vetted, accountable standard of care. As a result of clinical governance we can be reactive to any changes that are needed.

The safest formulation is only as safe as the person delivering it. A trained practitioner screens correctly, cannulates and mixes using proper aseptic technique and PPE, recognizes and manages reactions, and follows protocol every time. Training is what turns a good protocol into a safe, repeatable patient experience.

Evidence of clinical governance, qualified, trained medical staff on site, thorough screening and proper prescribing, and adherence to recognized brand and clinical standards. In the UK, to deliver elective IV therapy the clinic will need to be CQC registered, this is important to ensure regulatory compliance. In practice, if a provider screens you carefully before treating you, that is the clearest sign you are in safe hands.